- |||||||||| 5-fluorouracil / Generic mfg.
SUCCESSFUL MANAGEMENT OF A CASE OF HEREDITARY ANGIOEDEMA TRIGGERED BY CHEMOTHERAPY (Monitor 6; Hall A) - Sep 29, 2024 - Abstract #ACAAI2024ACAAI_664; Case Description: We present a case of a 49 year-old woman with HAE with reduced C1 inhibitor and recently diagnosed diffuse large B cell lymphoma who presented to Allergy Clinic for management of HAE after initiation of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)...Lanadelumab and pd-C1INH combination represents a potential option for prophylaxis of HAE during chemotherapy. Our case also highlights that icatibant should not be used for HAE prophylaxis.
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: The Effects of L-Tartaric Acid on Ovarian Histostereological and Serum Hormonal Analysis in an Animal Model of Polycystic Ovary Syndrome. (Pubmed Central) - Sep 28, 2024 Forty adult Sprague Dawley rats were randomly divided into four groups including controls (no intervention), Tartaric acid (40mg/Kg/day from day 21 onwards for 39 days), PCOS (21 days letrozole and then normal saline orally for 39 days), and PCOS?+?Tartaric acid...Furthermore, tartaric acid improved the serum levels of LH, estradiol, progesterone, and testosterone (p-value?<?0.05). The obtained findings may suggest tartaric acid as a novel strategy for PCOS management, although further studies are necessary.
- |||||||||| Piqray (alpelisib) / Novartis, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Gastric Metastasis from Breast Cancer Detected on 18F-FDG PET-CT A Rare Finding (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2580; This can lead to misdiagnosis of metastatic disease and insufficient treatment of the patient, which can later lead to disease progression or recurrence. Therefore, any abnormal metabolically active thickening in the stomach must be evaluated thoroughly even though it might appear innocuous.
- |||||||||| letrozole / Generic mfg.
Journal: Polysaccharide-fecal microbiota-based colon-targeted self-nanoemulsifying drug delivery system of curcumin for treating polycystic ovarian syndrome. (Pubmed Central) - Sep 24, 2024 Pharmacokinetic and pharmacodynamic evaluation was carried out on letrozole-induced female Wistar rats...The pharmacodynamic study indicated excellent recovery/reversal in the rats treated with CCM-CT-S-SNEDDS low and high dose containing FME (group 13 and group 14) in a dose-dependent manner. The developed formulation showcasing its improved bioavailability, targeted action, and therapeutic activity in ameliorating PCOS can be utilized as an adjuvant therapy for developing a dosage form, scale-up, and technology transfer.
- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Myo-Inositol for Infertility in PCOS (clinicaltrials.gov) - Sep 21, 2024 P=N/A, N=168, Recruiting, The developed formulation showcasing its improved bioavailability, targeted action, and therapeutic activity in ameliorating PCOS can be utilized as an adjuvant therapy for developing a dosage form, scale-up, and technology transfer. Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche
Journal: Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study. (Pubmed Central) - Sep 20, 2024 A 54-year-old postmenopausal female patient with recurrent breast cancer and metastasis was treated with trastuzumab and paclitaxel (12 cycles), followed by trastuzumab maintenance therapy (71 cycles)...Oral therapy with lapatinib and letrozole was prescribed for a year to treat the breast cancer, along with the lesions and enhanced nodules observed in the patient's lungs, liver, and bones...This case report demonstrates the long-term efficacy of T-DM1 and its satisfactory safety profile. Overall, it provides valuable insights into the management of and challenges faced during the treatment of recurrent breast cancer with metastasis.
- |||||||||| atirmociclib (PF-07220060) / Pfizer, tagtociclib (PF-07104091) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: C4391002: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (clinicaltrials.gov) - Sep 20, 2024 P1/2, N=192, Active, not recruiting, Overall, it provides valuable insights into the management of and challenges faced during the treatment of recurrent breast cancer with metastasis. Recruiting --> Active, not recruiting | Trial completion date: Dec 2026 --> Aug 2026 | Trial primary completion date: Dec 2026 --> Aug 2026
- |||||||||| Journal, Adverse events: Risk of ocular adverse events with aromatase inhibitors. (Pubmed Central) - Sep 19, 2024
Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.
- |||||||||| HRS-8080 / Jiangsu Hengrui Pharma, HRS-6209 / Jiangsu Hengrui Pharma, HRS-1358 / Jiangsu Hengrui Pharma
Enrollment open, Combination therapy, Metastases: A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients (clinicaltrials.gov) - Sep 19, 2024 P1/2, N=528, Recruiting, This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities. Not yet recruiting --> Recruiting
- |||||||||| bireociclib (XZP 3287) / Sihuan Pharmaceutical
Enrollment closed, Enrollment change, Trial completion date: A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (clinicaltrials.gov) - Sep 19, 2024 P1/2, N=402, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=300 --> 402 | Trial completion date: Dec 2022 --> Dec 2025
- |||||||||| Ameile (aumolertinib) / Jiangsu Hansoh Pharma
Multiple primary cancers (MPC) of breast and lung with primary EGFR T790M mutation Responded to Aumolertinib: A case report (Hall 407) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1306; For lung adenocarcinoma, she commenced treatment with pemetrexed plus carboplatin for 1 cycle, starting in October 2022, in conjunction with fluvestrant...For Breast cancer (cT2N1Mx Luminal B), considering the enlargement of the breast tumor that letrozole therapy previously, she received endocrine therapy with fluvestrant 500mg once every 28 days... This report presents the first case of applying aumolertinib for primary EGFR T790M mutations in patients with MPC of breast and lung, offering a promising treatment approach for the future survival of such patients.
- |||||||||| BRAF mutation in HR positive HER2 negative advanced breast cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1090;
She received second line Abemaciclib and Fulvestrant but progressed rapidly after 3 months...Clinical resistance to Dabrafenib and Trametinib was most likely associated with acquisition of the TYW1-BRAF and RABEP1-BRAF fusion genes...We report a rare case of breast cancer with BRAF mutation in which genomic profiling was used to direct therapy and the excellent response to treatment. Serial molecular profiling identified a novel BRAF fusion as the likely acquired resistance to BRAF inhibitors.
- |||||||||| Kisqali (ribociclib) / Novartis
Breast Carcinoma disguised as Systemic Sclerosis: A case report of unusual Paraneoplastic Syndrome (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1088; However, the disease progressed, and treatment was shifted to mycophenolate mofetil and Nintedanib...The first line of treatment with ribociclib and letrozole was initiated...The lack of response to conventional systemic sclerosis therapy but improvement with the underlying malignancy treatment suggests the case's possible paraneoplastic origin. This case report may further improve awareness of the natural course of the disease, preventing a potential cancer treatment delay.
- |||||||||| Kisqali (ribociclib) / Novartis
Ethnicity assessment of ribociclib pharmacokinetics in advanced breast cancer patients (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_413; In addition, at 400 mg dose, PK exposure (AUC, C max and/or C trough ) in Japanese patients was comparable to non-Japanese Asian patients (A2115) and global patients (the sample size in A2115 was small). Conclusions Considering ribociclib PK variability and inter-study variabilities, PK exposure of ribociclib were largely comparable between Caucasian and Asian patients with aBC.
- |||||||||| letrozole / Generic mfg.
Journal: True empty follicle syndrome is a subtype of oocyte maturation abnormalities. (Pubmed Central) - Sep 4, 2024 The treatment approaches included letrozole-primed IVM, follicle-stimulating hormone (FSH)-human chorionic gonadotrophin (hCG)-primed IVM, and conventional IVF...These conditions are observed in OMAs due to defects in the oocyte machinery. The proposed flowchart provides a comprehensive classification approach for various forms of EFS.
- |||||||||| LOXO-783 / Eli Lilly
Enrollment closed, Enrollment change, Combination therapy, Monotherapy, Metastases: PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) - Sep 4, 2024 P1, N=193, Active, not recruiting, The proposed flowchart provides a comprehensive classification approach for various forms of EFS. Recruiting --> Active, not recruiting | N=400 --> 193
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases. (Pubmed Central) - Sep 3, 2024 After the standard first-line treatment including albumin-bound paclitaxel, trastuzumab and pertuzumab, and a second-line treatment involving pyrotinib, capecitabine, and radiotherapy did not produce the desired results, the patient was then administered anlotinib in combination with pyrotinib and letrozole as a third-line treatment, which led to a partial response (PR). The findings suggest that anti-angiogenic therapy, specifically anlotinib, could be regarded as a promising therapeutic option for BC patients with BM.
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, Imbruvica (ibrutinib) / AbbVie, J&J
Dual Oncologic Challenges: Managing Chronic Lymphocytic Leukemia With Concurrent Melanoma and Breast Cancer: A Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_504; This case underscores the complex interplay between hematologic malignancies and solid tumors, highlighting the increased susceptibility to second primary malignancies in patients with CLL. It emphasizes the challenges of diagnostic workup and management of these patients, the need for interdisciplinary approaches, and the need for further research into preventive and treatment strategies for these intricate oncology cases.
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion, HEOR, Combination therapy, Real-world evidence, Real-world, Metastases: Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy (clinicaltrials.gov) - Aug 23, 2024 P=N/A, N=813, Completed, As certain eligible groups had a prognosis similar to non-eligible patients, it might be interesting to explore additional patient groups for CDK4/6i therapy. Active, not recruiting --> Completed
- |||||||||| Kisqali (ribociclib) / Novartis
Journal: Metastasis of breast cancer to the thyroid gland. (Pubmed Central) - Aug 22, 2024 Diagnosis involves imaging, FNAB, and immunohistochemistry. Treatment options include surgery, radiotherapy, and chemotherapy, but the prognosis is generally poor.
|